Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Complete-response-letter deficiency list arrived with a site-change that invalidates stability claims for pediatric-plan strategist. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on to drop a secondary in a 505(b)(2) program relying on literature plus a bridging study.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. A site-change that invalidates stability claims is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given complete-response-letter deficiency list. 2. A site-change that invalidates stability claims is the event in complete-response-letter deficiency list that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences. 3. Complete-response-letter deficiency list shows a one-file miss after a site-change that invalidates stability claims, not a Clinical and Evidence Strategy program failure. 4. Complete-response-letter deficiency list cannot decide to drop a secondary yet after a site-change that invalidates stability claims; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether complete-response-letter deficiency list supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after a site-change that invalidates stability claims). If complete-response-letter deficiency list cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. Do not invent missing evidence a 505(b)(2) program relying on literature plus a bridging study does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for pediatric-plan strategist - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in complete-response-letter deficiency list that a second reviewer can re-perform